These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 38290659

  • 1. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
    Liu ZD, Shi YH, Xu QC, Zhao GY, Zhu YQ, Li FX, Ma MJ, Ye JY, Huang XT, Wang XY, Xu X, Wang JQ, Zhao W, Yin XY.
    Cancer Lett; 2024 Mar 31; 585():216640. PubMed ID: 38290659
    [Abstract] [Full Text] [Related]

  • 2. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance.
    Ma MJ, Shi YH, Liu ZD, Zhu YQ, Zhao GY, Ye JY, Li FX, Huang XT, Wang XY, Wang JQ, Xu QC, Yin XY.
    Oncogene; 2024 Jul 31; 43(31):2405-2420. PubMed ID: 38914663
    [Abstract] [Full Text] [Related]

  • 3. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M, Weng L, Xu G, Wu S, Liu B, Yin X, Mao A, Zou X, Wang Z.
    J Cell Physiol; 2021 Oct 31; 236(10):6868-6883. PubMed ID: 33629745
    [Abstract] [Full Text] [Related]

  • 4. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
    Shi YH, Xu QC, Zhu YQ, Liu ZD, Zhao GY, Liu Q, Wang XY, Wang JQ, Xu X, Su Q, Lai JM, Huang CS, Yin XY.
    Mol Ther; 2023 Feb 01; 31(2):503-516. PubMed ID: 36384875
    [Abstract] [Full Text] [Related]

  • 5. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 6. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X, Zhao P, Wang C, Xin B.
    Biochem Biophys Res Commun; 2019 Mar 19; 510(4):508-514. PubMed ID: 30737032
    [Abstract] [Full Text] [Related]

  • 7. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 19; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 8. The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment.
    Feng M, Jiao Q, Ren Y, Liu X, Gao Z, Li Z, Wang Y, Zhao M, Bi L.
    Cell Death Dis; 2024 Oct 18; 15(10):758. PubMed ID: 39424627
    [Abstract] [Full Text] [Related]

  • 9. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S, Ueda T, Komuro A, Honda M, Sugisawa R, Okada H.
    Cell Death Dis; 2024 Feb 12; 15(2):131. PubMed ID: 38346958
    [Abstract] [Full Text] [Related]

  • 10. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
    Panzeri V, Manni I, Capone A, Naro C, Sacconi A, Di Agostino S, de Latouliere L, Montori A, Pilozzi E, Piaggio G, Capurso G, Sette C.
    Mol Oncol; 2021 Feb 12; 15(2):579-595. PubMed ID: 33159833
    [Abstract] [Full Text] [Related]

  • 11. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.
    Mao X, Xu J, Xiao M, Liang C, Hua J, Liu J, Wang W, Yu X, Meng Q, Shi S.
    Redox Biol; 2024 Jul 12; 73():103200. PubMed ID: 38781729
    [Abstract] [Full Text] [Related]

  • 12. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis.
    Li G, She FF, Liao CY, Wang ZW, Wang YT, Wu YD, Huang XX, Xie CK, Lin HY, Zhu SC, Chen YH, Wu ZH, Chen JZ, Chen S, Chen YL.
    Cell Death Dis; 2024 Oct 11; 15(10):742. PubMed ID: 39394197
    [Abstract] [Full Text] [Related]

  • 13. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.
    Basu R, Kulkarni P, Swegan D, Duran-Ortiz S, Ahmad A, Caggiano LJ, Davis E, Walsh C, Brenya E, Koshal A, Brody R, Sandbhor U, Neggers SJCMM, Kopchick JJ.
    Int J Mol Sci; 2024 Jul 06; 25(13):. PubMed ID: 39000545
    [Abstract] [Full Text] [Related]

  • 14. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P, Mannangatti P, Das SK, Fisher PB, Emdad L.
    Adv Cancer Res; 2023 Jul 06; 159():285-341. PubMed ID: 37268399
    [Abstract] [Full Text] [Related]

  • 15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.
    Gastroenterology; 2015 Dec 06; 149(7):1932-1943.e9. PubMed ID: 26255562
    [Abstract] [Full Text] [Related]

  • 16. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B.
    Cancer Lett; 2017 Jul 28; 399():1-9. PubMed ID: 28428074
    [Abstract] [Full Text] [Related]

  • 17. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
    Fu D, Yan J, Zhang Z, Liu Y, Ma X, Ding J, Yang S, Zhao R, Chang A, Gao C, Liu J, Zhao T, Wang X, Huang C, Gao S, Ma Y, Tang B, Feng Y, Wang H, Hao J.
    Cancer Biol Med; 2023 Jun 27; 20(8):599-626. PubMed ID: 37381714
    [Abstract] [Full Text] [Related]

  • 18. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S, Ueda T, Komuro A, Amano H, Honda M, Kawazu M, Okada H.
    Mol Cancer Res; 2023 May 01; 21(5):444-457. PubMed ID: 36757299
    [Abstract] [Full Text] [Related]

  • 19. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
    Patzak MS, Kari V, Patil S, Hamdan FH, Goetze RG, Brunner M, Gaedcke J, Kitz J, Jodrell DI, Richards FM, Pilarsky C, Gruetzmann R, Rümmele P, Knösel T, Hessmann E, Ellenrieder V, Johnsen SA, Neesse A.
    EBioMedicine; 2019 Feb 01; 40():394-405. PubMed ID: 30709769
    [Abstract] [Full Text] [Related]

  • 20. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wu L, Ge Y, Yuan Y, Li H, Sun H, Xu C, Wang Y, Zhao T, Wang X, Liu J, Gao S, Chang A, Hao J, Huang C.
    Cancer Lett; 2022 Nov 01; 548():215864. PubMed ID: 35981571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.